Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Repros Therapeutics Inc. Business Wire BENSALEM, Pa. -- October 24, 2013 Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. (“Repros” or the “Company”) (NASDAQ:RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Repros concerning the Company’s operations and financial prospects. Repros is a development stage biopharmaceutical company engaged in the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product portfolio includes Androxal – an oral therapy for the treatment of low testosterone due to secondary hypogonadism. Androxal is currently in Phase III clinical trials. The investigation is related to the Company’s recent announcement that the Food and Drug Administration has raised concerns about the reliability of some of the clinical data collected during Androxal’s Phase III pivotal efficacy studies, ZA-301 and ZA-302. Previously, in a press release the Company issued on September 18, 2013, Repros had stated that “the Company is completely satisfied that all data entered into the data base for study ZA-301 will pass any scrutiny the FDA chooses to apply.” On October 22, 2013, Repros disclosed that the FDA has instructed Repros to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302 as evidence of pivotal efficacy. In addition, the FDA has instructed Repros to submit additional study data for Androxal, which will delay the submission of the Company’s New Drug Application until the third or fourth quarter of 2014. Following this news, the price of Repros stock dropped more than 27%, or $6.57 per share, to a closing price of $17.12 on October 23, 2013. If you purchased Repros shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com. Contact: Law Offices of Howard G. Smith Howard G. Smith, Esquire (215) 638-4847 (888) 638-4847 email@example.com www.howardsmithlaw.com
Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Repros Therapeutics Inc.